What is Cogent Biosciences, Inc.'s gain/loss on asset sales?

Cogent Biosciences, Inc. (COGT) reported gain/loss on asset sales of -$135K in Q1 2026.

What does gain/loss on asset sales mean?

Gains or losses on asset disposals removed from operating cash flow — the cash impact is captured in investing activities.

Cogent Biosciences, Inc. COGT Gain/Loss on Asset Sales

Gain/Loss on Asset Sales at other companies

Scholar RockSRRK

-$3K—

BillionToOne, Inc. BLLN

-$57K-1,800%

Jazz PharmaceuticalsJAZZ

——

Other financials

Income statement

See full

Operating income-$103.6M-38.3%

Net income-$97.4M-35.2%

EPS (diluted)-$0.53-1.9%

Balance sheet

See full

Cash & equivalents$241.2M+91.4%

Total debt$15.5M-9.4%

Total equity$607.7M+177%

Total assets$903.0M+218%

Cash flow

See full

Operating cash flow-$86.9M-30.6%

CapEx$449.0K-17.9%

Free cash flow-$87.3M-30.2%

Valuation

See full

Market cap$5.9B+816%

Enterprise value$5.68B+951%

P/S749.8×—

Profitability

See full

Operating margin-1,044.3%—

Net margin-950.4%—

FCF margin-184.7%—

Returns & leverage

See full

Return on equity-85.7%+1.7pp

Debt / equity0×-0.1×

Current ratio15.1×+10.0×

Where this comes from

Reported directly by Cogent Biosciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:GainLossOnSaleOfPropertyPlantEquipment.

The official record: Cogent Biosciences, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Cogent Biosciences, Inc.'s gain/loss on asset sales.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Cogent Biosciences, Inc.'s gain/loss on asset sales?: Cogent Biosciences, Inc. (COGT) reported gain/loss on asset sales of -$135K in Q1 2026.
What does gain/loss on asset sales mean?: Gains or losses on asset disposals removed from operating cash flow — the cash impact is captured in investing activities.